PROTOKINETIX INC - PKTX STOCK NEWS

ProtoKinetix, a clinical-stage biomedical company, announced the successful enrollment completion of its Phase 1 clinical trial for PKX-001 aimed at type 1 diabetes islet cell transplants at the University of Alberta. The trial has achieved primary safety objectives, and patient observation will continue for six months to evaluate secondary objectives. Dr. James Shapiro leads the trial, expressing enthusiasm for the anti-aging glycopeptide molecule's potential benefits. Data collection and analysis will follow the observation period.

ProtoKinetix, a clinical-stage biomedical company, will hold its Annual General Meeting (AGM) virtually on February 11, 2022, at 4:00 p.m. EST. This decision was made due to ongoing COVID-19 concerns, with no in-person attendance permitted. Shareholders are encouraged to review the definitive proxy materials filed with the Securities and Exchange Commission on December 30, 2021. For more details, shareholders can visit www.virtualshareholdermeeting.com/PKTX2022.

ProtoKinetix, a clinical-stage biomedical company, has selected two formulations of its Anti-Aging Glycopeptide (AAGP®) for preclinical efficacy testing aimed at treating dry eye disease and ocular inflammation. The testing will be conducted by EyeCRO in Oklahoma City, expected to finish by mid-January 2022. Following this, the lead formulation will undergo GLP toxicology assessments for FDA submission. The company emphasizes its commitment to stockholder value creation and is enhancing its team with specialized consultants to support product commercialization and regulatory compliance.

ProtoKinetix (OTCQB: PKTX) announced a significant collaboration with IQVIA to expedite the clinical development of its AAGP® (PKX-001) for ocular conditions, including Dry Eye Disease and Age-related Macular Degeneration. This partnership aims to enhance the clinical trial process as PKX-001 progresses to Phase 1 testing. Leveraging prior successes with PKX-001 in Type 1 diabetes, the initiative seeks to optimize safety assessments for these new indications, presenting an opportunity for market expansion and improved investor confidence.

ProtoKinetix announced the resumption of Phase I clinical trials for AAGP® (PKX-001) treated islet cells at the University of Alberta, paused due to COVID-19. The trials aim to assess the safety and efficacy of PKX-001 in treating Type-1 diabetes, with the first patient of ten now enrolled in Phase 1b. Initial results demonstrated PKX-001's safety in a previous Phase 1a study. The trials also seek to optimize dosage and evaluate protection from tacrolimus toxicity.

ProtoKinetix (PKTX) has partnered with a global pharmaceutical firm to develop a topical ocular drug targeting dry eye disease (DED) using AAGP®. The company has completed essential studies, including ocular irritation tests and pre-clinical trials demonstrating efficacy. Upcoming tasks include finalizing formulations and obtaining FDA approval for clinical trials. The dry eye disease market, valued at approximately USD 4.5 billion in 2018, is projected to reach USD 6.2 billion by 2024, with an annual growth rate of 5.23%. This milestone is crucial for the commercialization of PKTX's DED program.

ProtoKinetix (OTCQB: PKTX), a clinical-stage biomedical company, announced a peer-reviewed research publication on AAGP® for retinal precursor cell transplantation, aiming to restore vision in models of blindness. Published in the Journal of Tissue Engineering and Regenerative Medicine, the study highlighted that AAGP® significantly improved cell survival and integration, showing threefold better performance in vision function tests compared to untreated cells. The research was led by renowned expert Dr. Kevin Gregory-Evans, underscoring the potential of AAGP® in regenerative medicine amidst a growing market for ophthalmic therapeutics.